Jiangxi Jemincare Group was approved to start US clinical trials of its SARS-CoV-2 neutralizing antibody, JMB2002, which was developed by the Jemincare Shanghai Research Center. The company published data in February showing that, in preclinical studies, JMB2002 showed strong prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques. In January, Jemincare started a China Phase I clinical trial of the candidate in healthy volunteers. The company is headquartered in Nanchang.

According to Jemincare, JMB2002 occupied the key epitope of the receptor binding domain (RBD) on the S1 subunit of the SARS-CoV-2 with human angiotensin-converting enzyme II (hACE2) binding interface. It showed efficacy against the three major mutant viruses now circulating, including the South African mutant (B.1.351), the UK mutant (B.1.1.7) and the Brazilian mutant (P.1) .

Founded in 1999, Jemincare focuses on R&D, production and market of modern Chinese medicine, biological agents and health care products. It has seven pharmaceutical bases, an international postdoctoral workstation, a CNAS certified national laboratory and five provincial engineering and technical centers R&D institutes that are located in Jiangxi, Beijing, Shanghai, Jiangsu and Zhejiang

Jemincare Group focuses on the R&D of new drugs with a pipeline aimed at diseases in cancer, central nervous system, respiratory system, cardiovascular and cerebrovascular systems. The company has establish its Research Center in Shanghai Zhangjiang Science City and has recruited over 400 R&D scientists to develop innovative drugs including biologics, novel small molecules, novel drug delivery system, generic drugs and traditional Chinese medicines.

See our other articles on Jemincare.

Disclosure: none.